The FDA will prioritize the full approval of the Pfizer COVID-19 vaccine


(HealthDay) —Pfizer Inc. announced Friday that the U.S. Food and Drug Administration has given priority review to its COVID-19 vaccine, positioning the vaccine for full approval in January.

The Pfizer vaccine has been given to more Americans than any other trait so far in the U.S. vaccination campaign. According to data from the U.S. Centers for Disease Control and Prevention, some 85 million people have been completely vaccinated under the two-dose Pfizer regimen.

A full approval of the Pfizer vaccine could help boost U.S. vaccination efforts. Some people who have been reluctant to receive a vaccine have said they are unwilling to get an experimental drug and that approval may also make it easier for employers, school districts and others to demand vaccination, Bloomberg News reported.

Right now, the Pfizer vaccine is only allowed as an emergency for people 12 years of age or older. Pfizer said it would seek full approval in those 12 to 15 years of age once the necessary six months of data are available after the second dose of vaccine.

Pfizer will apply for approval in the fall for the use of COVID-19 vaccines in children ages 2 to 11

More information:
Bloomberg News Article

Copyright © 2021 HealthDay. All rights reserved.

Citation: FDA will prioritize full approval of Pfizer COVID-19 vaccine (2021, July 19) recovered July 19, 2021 at pfizer-covid-.html

This document is subject to copyright. Apart from any fair treatment for the purposes of private study or research, no part may be reproduced without written permission. Content is provided for informational purposes only.

Source link